Search clinical trials for: TAK-831

Total 5201 results

Takeda

Recruiting

A Study About Fazirsiran in People With and Without Liver Problems

Hepatic Impairment

Hungary, Slovakia
Shire
Takeda Development Center Americas, Inc.

Completed

A Study of SHP655 (rADAMTS13) in Sickle Cell Disease (RAISE)

Sickle Cell Disease

United States
Takeda

Completed

A Study of Soticlestat in Adults With Liver Failure Compared to Those With Normal Liver Function

Healthy Volunteers | Hepatic Impairment

United States, Hungary
Takeda
Ovid Therapeutics Inc.

Completed

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies (ELEKTRA)

Epilepsy | Dravet Syndrome | Lennox-Gastaut Syndrome

United States, Canada, Israel, Poland, Spain, Australia, China, Portugal
Takeda

Completed

Safety of Ramelteon in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease | COPD

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IVA Thyroid Gland Papillary Carcinoma AJCC... and other conditions

United States
Takeda

Completed

TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability Study

Healthy Volunteers

United Kingdom
Antengene Biologics Limited

Recruiting

A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas

Advanced Solid Tumors | B-cell Non-Hodgkin Lymphomas

United States
Kissei Pharmaceutical Co., Ltd.
JCR Pharmaceuticals Co., Ltd.

Completed

A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

Anemia

Japan
Oncolys BioPharma Inc

Unknown

A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors

Solid Tumor

United States
Stealth BioTherapeutics Inc.

Completed

A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal Function

Normal and Impaired Renal Function

United States
Merck Sharp & Dohme LLC

Completed

A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])

Alzheimer's Disease
Amgen

Completed

Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis

Systemic Lupus Erythematosus | Nephritis

United States, Hong Kong, France, Malaysia, Mexico
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531

Alzheimer Disease

Japan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Young and Elderly Subjects

Alzheimer Disease

France
Cellectar Biosciences, Inc.

Withdrawn

Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma

Glioma

United States
Takeda
Takeda Development Center Americas, Inc.

Recruiting

A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Thrombotic Thrombocytopenic Purpura (TTP)

United States, Spain, Italy, Greece, United Kingdom, Argentina, Poland, Austria
Takeda

Completed

A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

China
Takeda

Completed

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants

Dose Finding Study

United States
Takeda

Terminated

Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Poland, Bulgaria, Romania, Canada, Hungary, Slovakia
Millennium Pharmaceuticals, Inc.

Completed

A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants

Healthy Volunteers

United States
Takeda

Active, not recruiting

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, Spain, Korea, Republic of, Taiwan, Japan, China, Italy, Germany, United Kingdom, Puerto Rico
National Cancer Institute (NCI)

Completed

Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

Refractory Pancreatic Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor G1 | Pancreatic Neuroendocrine Tumor G2

United States
Takeda

Terminated

A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of TAK-828 Escalating Multiple-Doses in Healthy Participants

Healthy Volunteers

United States
Takeda

Completed

Phase 2 Study of TAK-850 in Comparison With Influenza Hemagglutinin (HA) Vaccine in Healthy Adult Participants

Influenza Infection
Takeda

Terminated

TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes

Diabetes

United States, Peru, Argentina
Takeda
Shire; Takeda Development Center Americas, Inc.

Recruiting

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Thrombotic Thrombocytopenic Purpura (TTP)

China, United States, France, Japan, Poland, Germany, Austria, Spain, Italy, Switzerland, United Kingdom
Takeda

Completed

Exploratory Study of the Effect of Omega-3-acid Ethyl Esters (TAK-085) on Vascular Endothelial Function in Patients With Hyperlipidemia by Flow Mediated Dilation (Oasis Flow)

Hyperlipidemia

Japan
Takeda

Completed

TAK-935 Multiple Rising Dose Study in Healthy Participants

Epilepsy

United States
Takeda

Completed

Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935

Healthy Volunteers

United States
Takeda

Completed

A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy

Gastric Ulcer | Duodenal Ulcer

Japan
OBI Pharma, Inc

Recruiting

To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (EGFR)

Non-small Cell Lung Cancer

Taiwan
Cerevel Therapeutics, LLC

Recruiting

A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Schizophrenia

United States, Bulgaria, Hungary
Calithera Biosciences, Inc

Completed

A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults

Healthy Volunteers

United States
Shanghai Changzheng Hospital

Not yet recruiting

A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma
Exegenesis Bio

Recruiting

A Study of EXG102-031 in Patients With wAMD (Everest)

Neovascular (Wet) Age-related Macular Degeneration (nAMD)

United States
Chong Kun Dang Pharmaceutical

Completed

A Study to Investigate the Effect of Food on the PK, PD of CKD-381 in Healthy Volunteers

GERD

Korea, Republic of
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Japanese Males

Alzheimer Disease
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers

Muscle Loss

Canada
Cerevel Therapeutics, LLC

Recruiting

A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy

Apathy in Dementia

United States, Canada
Shire
Takeda Development Center Americas, Inc.

Active, not recruiting

A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy (EMBOLDEN)

Metachromatic Leukodystrophy (MLD)

United States, Canada, Belgium, Israel, Netherlands, United Kingdom, Germany, Spain, Japan, Brazil, Argentina, France, Greece, Italy
Swiss Group for Clinical Cancer Research

Completed

Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy

Prostate Cancer

Switzerland
Takeda

Completed

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of ENV8058 (TAK-058) in Healthy Participants

Dose Finding Study

United States
Cerevel Therapeutics, LLC

Recruiting

A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

Renal Impairment

United States
Cerevel Therapeutics, LLC

Recruiting

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine

Hepatic Impairment

United States
Altimmune, Inc.

Completed

Efficacy and Safety of ALT-801 in the Treatment of Obesity

Obesity/Overweight

United States
Stemline Therapeutics, Inc.

Completed

A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors

Solid Tumors

United States
Chong Kun Dang Pharmaceutical

Completed

Study to Evaluate the Safety and Pharmacokinetics of CKD-331

Hypertension and Dyslipidemia

Korea, Republic of
Amgen

Completed

AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy

Thrombocytopenia | Idiopathic Thrombocytopenic Purpura
Amgen

Completed

AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy

Thrombocytopenia | Idiopathic Thrombocytopenic Purpura

3

Subscribe